AstraZeneca (AZN) announced positive results from the phase III NIAGARA study, which evaluated Imfinzi in patients with muscle-invasive bladder cancer (MIBC).Study participants who were enrolled in the NIAGARA study were randomized to receive Imfinzi plus chemotherapy or chemotherapy alone before cystectomy (bladder removal surgery), followed by Imfinzi or no further treatment after surgery.The study achieved statistically significant and clinically meaningful improvement in its primary endpoint of event-fr ...